Pituitary apoplexy: a comprehensive analysis of 93 cases across functioning and non-functioning pituitary adenomas from a single-center

IF 3.3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Divya C. Ragate, Saba Samad Memon, Anurag Ranjan Lila, Vijaya Sarathi, Virendra A. Patil, Manjiri Karlekar, Rohit Barnabas, Hemangini Thakkar, Nalini S. Shah, Tushar R. Bandgar
{"title":"Pituitary apoplexy: a comprehensive analysis of 93 cases across functioning and non-functioning pituitary adenomas from a single-center","authors":"Divya C. Ragate, Saba Samad Memon, Anurag Ranjan Lila, Vijaya Sarathi, Virendra A. Patil, Manjiri Karlekar, Rohit Barnabas, Hemangini Thakkar, Nalini S. Shah, Tushar R. Bandgar","doi":"10.1007/s11102-024-01453-5","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>: Pituitary apoplexy (PA) is a rare clinical syndrome due to acute/subacute pituitary hemorrhage and/or infarction; data on PA in functioning pituitary adenoma (FPA) is scarce.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A retrospective record-review of details of PA in non-functioning (NFPA) and FPA managed at tertiary endocrine center.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>93 patients [56 males; 33.3% FPA: 5 acromegaly, 14 prolactinoma, and 12 Cushing’s Disease (CD)] diagnosed with PA were included. Median age was 40 years, with younger age of presentation in FPA. Type A (acute) [49.5%] and headache (78.5%) were the commonest presentations, with PA being the initial manifestation in 98.4% of NFPA. Median (range) Pituitary Apoplexy Score (PAS) was 2 (0–8). Median tumor diameter was 2.5 cm, with larger tumors in FPA (3.2 cm vs. 2.3 cm). 29 (46.7%) NFPA-PA and 14 (45.2%) FPA-PA patients [71% prolactinoma, 33% in CD, and none in acromegaly] were conservatively managed. In the NFPA cohort, those managed surgically had significantly higher PAS (4 vs. 1) and larger tumor size (2.6 vs. 1.8 cm); however, both arms had comparable recovery of neuro-visual, radiological, and hormonal outcomes. In FPA cohort, CD and acromegaly required definitive treatment, whereas prolactinomas were effectively managed (clinical and biochemical recovery) with oral cabergoline and glucocorticoids. Matching PAS cohorts (to overcome allocation bias for management approach) in macroadenomas (excluding prolactinoma) showed comparable neuro-deficit and hormonal recovery between surgical and conservative approaches.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>PA in FPA has distinct features and management issues. Carefully selected patients (PAS guided) in NFPA with PA for conservative management have comparable outcomes to surgery.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pituitary","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11102-024-01453-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

: Pituitary apoplexy (PA) is a rare clinical syndrome due to acute/subacute pituitary hemorrhage and/or infarction; data on PA in functioning pituitary adenoma (FPA) is scarce.

Methods

A retrospective record-review of details of PA in non-functioning (NFPA) and FPA managed at tertiary endocrine center.

Results

93 patients [56 males; 33.3% FPA: 5 acromegaly, 14 prolactinoma, and 12 Cushing’s Disease (CD)] diagnosed with PA were included. Median age was 40 years, with younger age of presentation in FPA. Type A (acute) [49.5%] and headache (78.5%) were the commonest presentations, with PA being the initial manifestation in 98.4% of NFPA. Median (range) Pituitary Apoplexy Score (PAS) was 2 (0–8). Median tumor diameter was 2.5 cm, with larger tumors in FPA (3.2 cm vs. 2.3 cm). 29 (46.7%) NFPA-PA and 14 (45.2%) FPA-PA patients [71% prolactinoma, 33% in CD, and none in acromegaly] were conservatively managed. In the NFPA cohort, those managed surgically had significantly higher PAS (4 vs. 1) and larger tumor size (2.6 vs. 1.8 cm); however, both arms had comparable recovery of neuro-visual, radiological, and hormonal outcomes. In FPA cohort, CD and acromegaly required definitive treatment, whereas prolactinomas were effectively managed (clinical and biochemical recovery) with oral cabergoline and glucocorticoids. Matching PAS cohorts (to overcome allocation bias for management approach) in macroadenomas (excluding prolactinoma) showed comparable neuro-deficit and hormonal recovery between surgical and conservative approaches.

Conclusion

PA in FPA has distinct features and management issues. Carefully selected patients (PAS guided) in NFPA with PA for conservative management have comparable outcomes to surgery.

垂体性脑瘫:对一家中心93例功能性和非功能性垂体腺瘤病例的综合分析
简介:垂体性脑瘫(PA)是一种罕见的临床综合征,由急性/亚急性垂体出血和/或梗死引起;有关功能性垂体腺瘤(FPA)垂体性脑瘫的数据很少。方法对三级内分泌中心收治的非功能性垂体腺瘤(NFPA)和功能性垂体腺瘤 PA 的详细情况进行回顾性记录回顾。结果共纳入 93 例诊断为 PA 的患者[56 例男性;33.3% 为功能性垂体腺瘤:5 例肢端肥大症、14 例催乳素瘤和 12 例库欣氏症(CD)]。中位年龄为 40 岁,FPA 患者的发病年龄更小。A型(急性)[49.5%]和头痛(78.5%)是最常见的表现,98.4%的 NFPA 最初表现为 PA。垂体性脑瘫评分(PAS)的中位数(范围)为 2(0-8)。肿瘤直径中位数为2.5厘米,FPA患者的肿瘤更大(3.2厘米对2.3厘米)。29例(46.7%)NFPA-PA患者和14例(45.2%)FPA-PA患者[71%为催乳素瘤,33%为CD,无肢端肥大症患者]接受了保守治疗。在 NFPA 队列中,手术治疗的患者 PAS 明显更高(4 对 1),肿瘤尺寸更大(2.6 对 1.8 厘米);不过,两组患者的神经视力、放射学和激素恢复情况相当。在FPA队列中,CD和肢端肥大症需要明确治疗,而催乳素瘤则通过口服卡麦角林和糖皮质激素得到了有效控制(临床和生化恢复)。大腺瘤(不包括泌乳素瘤)的匹配 PAS 队列(以克服管理方法的分配偏差)显示,手术和保守方法的神经功能缺失和激素恢复情况相当。精心挑选的 NFPA 患者(PAS 指导下)接受保守治疗与手术治疗效果相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pituitary
Pituitary 医学-内分泌学与代谢
CiteScore
7.10
自引率
7.90%
发文量
90
审稿时长
6 months
期刊介绍: Pituitary is an international publication devoted to basic and clinical aspects of the pituitary gland. It is designed to publish original, high quality research in both basic and pituitary function as well as clinical pituitary disease. The journal considers: Biology of Pituitary Tumors Mechanisms of Pituitary Hormone Secretion Regulation of Pituitary Function Prospective Clinical Studies of Pituitary Disease Critical Basic and Clinical Reviews Pituitary is directed at basic investigators, physiologists, clinical adult and pediatric endocrinologists, neurosurgeons and reproductive endocrinologists interested in the broad field of the pituitary and its disorders. The Editorial Board has been drawn from international experts in basic and clinical endocrinology. The journal offers a rapid turnaround time for review of manuscripts, and the high standard of the journal is maintained by a selective peer-review process which aims to publish only the highest quality manuscripts. Pituitary will foster the publication of creative scholarship as it pertains to the pituitary and will provide a forum for basic scientists and clinicians to publish their high quality pituitary-related work.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信